An amino acid substitution that blocks the deacylation step in the enzyme mechanism of penicillin-binding protein 5 of Escherichia coli  by Broome-Smith, Jenny & Spratt, Brian G.
Volume 165, number 2 PBBS 1107 January 1984 
An amino acid substitution that blocks the deacylation step in 
the enzyme mechanism of penicillin-binding protein 5 of 
Escherichia coli 
Jenny Broome-Smith and Brian G. Spratt 
Microbial Genetics Group, School of Biological Sciences, University of Sussex, Falmer, Brighton BNI 9QG, 
Sussex, England 
Received 21 November 1983 
A mutant of Escherichia coli has been described that produces an altered form of penicillin-binding protein 
5 which still binds penicillin but is unable to catalyse the release of the bound penicilloyl moiety. We show 
that the mutation is caused by a single nucleotide transition that results in a change from glycine at residue 
105 of the wild-type sequence of penicillin-binding protein 5 to aspartate in the mutant. 
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1. INTRODUCTION 
Penicillin-binding proteins (PBPs) catalyse the 
final stages of peptidoglycan synthesis [l-3]. In 
Escherichia coli PBPs lA/lB, 2 and 3 have been 
shown to be the killing targets of the fl-lactam an- 
tibiotics and to catalyse the polymerisation of pep- 
tidoglycan precursors and their incorporation into 
the cell wall by transpeptidation [2-41. The PBPs 
of lower molecular mass (PBPs 4, 5 and 6) are non- 
essential for bacterial growth and catalyse the D- 
alanine carboxypeptidase reaction [2,3]. 
Studies with the D-alanine carboxypeptidases of
several bacteria have supported the hypothesis in 
[5] that penicillin acts an an analogue of the acyl- 
D-alanyl-D-alanine moiety of the pentapeptide 
sidechain of the substrates of penicillin-sensitive 
enzymes [3,6-91. With these enzymes (e.g., PBP 5 
of Bacillus subtilis and PBPs 5 and 6 of E. coli) 
penicillin has been shown to acylate an active site 
residue to form a relatively stable penicilloyl-en- 
zyme complex that is analogous to the transient 
acyl-enzyme intermediate formed with substrate 
[7,8]. With some PBPs (e.g., PBPs 5 and 6 of E. 
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coli and PBP 4 of Staphylococcus aureus) there is 
a slow enzymically catalysed release of the bound 
penicilloyl moiety as penicilloic acid with the 
regeneration of the active enzyme [lo-121. These 
PBPs therefore catalyse a very weak P-lactamase 
reaction. 
In the case of PBP 5 of E. coli (D-alanine car- 
boxypeptidase 1A) the penicilloyl-enzyme complex 
has a half life of 5 min at 30°C [lo]. Authors in 
[13] have described a mutation (dacA11191) that 
results in the production of an altered PBP 5 which 
still binds penicillin but is blocked in the release of 
the bound penicilloyl moiety. The mutant PBP 5 
fails to catalyse the D-alanine carboxypeptidase 
reaction as the hydrolysis of the acyl-enzyme form- 
ed with substrate is also blocked and the acyl- 
enzyme accumulates [3,13]. We have recently ob- 
tained the amino acid sequence of PBP 5 from the 
nucleotide sequence of the dacA gene ([I41 and in 
preparation). We here show that the block in the 
deacylation step of the enzyme mechanism of PBp 
5, caused by the dacA11191 mutation, is due to a 
change of a glycine at residue 105 of the wild-type 
PBP 5 to aspartate in the mutant. 
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2. MATERIALS AND METHODS 
2.1. Bacterial strains and plasmids 
The following E. coli strains were used. 
TMRL1222, proA purB his thi galK lacy rpsL 
dacAlll91 dacB [13]; SP5003, his supF srl::TnlO 
recA56 A(lip-dacA-rodA)/XdrodAI [ 151. pBS25 
contains the E. coli dacA gene cloned as a 2.7-kb 
chromosomal DNA fragment from a partial 
SauIIIA digest in the low copy number plasmid 
pSClO5 [16]. pBS59 contains the dacA gene on a 
1597-base pair (bp) BamHI-EcoRI fragment in- 
serted in the low copy number vector pLG338 [ 171. 
Restriction maps of these plasmids are shown in 
fig. 1. 
2.2. Assay of PBPs 
PBPs were assayed in whole cells or purified cell 
envelopes using [3H]benzylpenicillin (10.5 
Ci/mmol; kindly provided by Dr Louis Nisbet of 
Smith, Kline, Beckman Corporation) as in [lo, 181. 
The mutant and wild-type forms of PBP 5 were 
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Fig. 1. Structure of pBS25 and pBS59. The location and 
direction of transcription of the kanamycin 
phosphotransferase gene (Km) and the &CA gene are 
indicated on the plasmid maps by the arrows. The solid 
blocks indicate the chromosomal DNA inserts carried by 
the plasmids. pJBS608 has an identical structure to 
pBS25 except hat it carries the dacA 11191 mutation (see 
text). The 1597-bp BarnHI-EcoRI fragment that 
encodes PBP 5, the location of the coding region, and 
the features of the structure of PBP 5 are shown at the 
bottom of the figure. The unhatched part of the line 
diagram of PBP 5 represents the 29 amino acid signal 
peptide [2,14]. 
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distinguished by their rate of release of bound 
[14C]benzylpenicillin. PBPs were labelled in whole 
cells for 10 min at 30°C with [3H]benzylpenicillin 
(50 pg/ml final concentration), a lOO-fold excess of 
unlabelled benzylpenicillin was added, and incuba- 
tion was continued for a further 30 min at 30°C. 
SDS solubiliser buffer [lo] was added and the 
PBPs were fractionated on a 12% SDS 
polyacrylamide gel and the amount of [3H]ben- 
zylpenicillin remaining bound to PBP 5 was 
detected by fluorography. Under these conditions 
less than 5% of the [3H]benzylpenicillin remained 
bound to the wild-type PBP 5 whereas there was 
no substantial release from the mutant PBP 5. The 
affinity of the mutant and wild-type PBP 5 for 
benzylpenicillin was measured by incubating cell 
envelopes with 2-fold increasing concentrations of 
[3H]benzylpenicillin for 10 min at 30°C and quan- 
titating the amount of antibiotic bound as in [lo]. 
2.3. Manipulation of DNA and DNA sequencing 
The preparation of plasmid DNA and tech- 
niques for the manipulation of DNA and trans- 
formation have been described [ 15,171. DNA 
fragments to be sequenced were cloned into the 
replicative form of bacteriophage M13mp9 [ 191 
and single-stranded template DNA was prepared 
and sequenced using the ‘dideoxy’ chain- 
termination method [20]. 
3. RESULTS 
3.1. Transfer of the dacA1 I191 mutation from the 
chromosome onto pBS25 
Strain TMRL1222 carries the dacA11191 muta- 
tion and produces an altered PBP 5 that still binds 
benzylpenicillin but is defective in the enzyme 
catalysed release of the bound penicilloyl moiety 
[ 131. The wild-type dacA gene has been cloned as 
a 2.7-kb DNA fragment in pSClO5 to produce 
pBS25 [20]. E. coli TMRL1222 (pBS25) grows as 
spherical cells which are killed by concentrations 
of sodium lauroylsarcosinate that have no effect 
on the viability of normal rod-shaped cells. This 
effect is due to the elevated levels of PBP 5 [16]. 
Transfer of the dacA111191 mutation from the 
chromosome onto pBS25 by reciprocal recombina- 
tion, followed by plasmid segregation, should 
result in cells that overproduce the mutant en- 
zymatically inactive form of PBP 5. Overproduc- 
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tion of enzymatically inactive PBP 5 is not ex- 
pected to result in the growth of E. coli as spherical 
cells and this provides a selection for the in vivo 
transfer of the &CA 11191 mutation to pBS25 by 
plating strain TMRL1222 (pBS25) on penassay 
agar containing 1% sodium lauroylsarcosinate 
where only rod-shaped cells will survive. In prac- 
tice strain TMRL1222 (pBS25) plated on the above 
agar with a frequency of about 10m4. The majority 
of the survivors were rod-shaped and produced 
elevated levels of the mutant form of PBP 5. 
Plasmid carrying the dacA11191 mutation was 
prepared from one of these strains and was 
purified genetically by transformation into strain 
SP5003, which is deleted of the entire 
chromosomal dacA gene [ 151. SP5003 carrying the 
plasmid (pJBS608) produced elevated levels of the 
mutant form of PBP 5 (fig.2). 
The half time for the release of the penicilloyl 
moiety from the wild-type and mutant forms of 
PBP 5 at 30°C were 4 min and about 60 min, 
respectively (fig.2). The affinities of the mutant 
and wild-type forms of PBP 5 for benzylpenicillin 
were estimated by measuring the concentration re- 
quired to obtain 50% saturation of the PBPs using 
cell envelopes prepared from the overproducing 
strains SP5003(pBS25) and SP5003(pJBS608). The 
affinity of the mutant form of PBP 5 for ben- 
zylpenicillin was 2 times less than that of the wild- 
type enzyme. 
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3.2. Location of the dacAlII91 mutation to a 
BstEII-BglIZ fragment and its sequencing 
The location of the mutation that prevents the 
release of bound penicillin was determined by 
reconstructing the dacA gene from fragments of 
the wild-type and mutant genes. The 683-bp 
BstEII-BgflI fragment from pJBS608 was purified 
and ligated to the purified large BstEII-BglIII 
fragment of pBS69 to regenerate the dacA gene 
(see fig.1). The ligation mixture was used to 
transform E. coli SP5003 to kanamycin resistance. 
Transformants were examined for the production 
of the mutant or wild-type forms of PBP 5 by 
measuring the rate of release of bound [14C]ben- 
zylpenicillin. Thirteen out of 26 transformants 
produced by the mutant form of PBP 5 and all of 
these contained plasmids that were the same size as 
pBS59 and were indistinguishable from pBS59 by 
restriction mapping. They must therefore have 
arisen by the replacement of the 683-bp 
BstEII-BglII fragment of wild-type dacA in pBS59 
with the corresponding fragment from the mutant 
dacA gene of pJBS608. The dacA11191 mutation 
is therefore located in the 683-bp BstEII-BgfII 
fragment. 
To sequence this region, the 1247-bp 
BarnHI-BgfiI fragment was isolated from pJB608 
(fig.1) and was digested with SauIIIA. The 
SauIIIA fragments were cloned into the BamHI 
site of the replicative form of M13mp9 
Fig. 2. Release of bound [3H]benzylpenicilloy1 moiety by wild-type and mutant forms of PBP 5. Cell envelopes of 
SP5003(pBS25) (tracks a-g) and SP5003 (pJBS608) (tracks h-n) were incubated with [3H]benzylpenicillin (30 pg/ml 
final concentration) for 10 min at 3O”C, a lOO-fold excess of unlabelled benzylpenicillin was added, and samples were 
taken after further incubation at 30°C for 0 (a,h); 5 (b,i); 10 (c,j); 20 (d,k); 30 (e,l); 45 (f,m) and 60 min (g,n). The 
PBPs were fractionated on a 12% SDS polyacrylamide gel and the level of radioactivity bound to each protein was 
detected by fluorography as in [lo]. 
187 
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80 100 (D) 
GNPVFKGSSLMFLKPGHQVPVSQLIRGINLQSGNDACVA 
GGTAACCCGGTGTTPAAAGGTTCTTCGCTGATGTTCCTCCTCAMCCGGGCATGCAGGT~CGGTTTCTCAGCTGATCCGCGGTATTMCCTGCAATCG~TMCGATGCTTGTG~GCC 
570 sali 590 60;) 61;1 62;) 6.3; 
64;) 
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120 140 
MADFAAGSQDAFVGLMNSYVNALGLKNTHFQTVHGLDADG 
ATGGCCGATTTTGCCGCTGGTAGCCAGGACGCTTTTGT~GCTTGATGAACAGCTACGTTMCGCACTGGGCCTGA~TACCCACT~CAGACGGTACA~G~TGGATGCTGATGGT 
69; 700 710 72;) 73;) 74; 75; 760 170 1sa 790 SO;, 
200 220 
RNGLLWDNSLNVDGIKTGHTDKAGYNLVASATEGQMRLIS 
CGTAACGGCCTGTTATGGGATMCAGCCTGMTG~GACGGCATC~CCGGACACACTGAC~GCAGGTTACAACCT~~CT~TGCGACTGMGGC~GA~CGCTTGA~T 
930 940 95;) 96;) 97; 980 990 1000 1010 1020 103; 104; 
240 260 
AVMGGRTFKGREAESKKLLTWGFRFFETVNPLKVGKEFAS 
GCGGTAATGGGCGGACGTACTTTTAAAGGCCGTGAAGCCGAAAGTAAAAAA C GCTMCCTGGGGCTTCCGTTTCTTTGAAACCGTTMCCCACTG~GTA~T~GAGT~GCCTCT 
105; 106;) 1070 1080 1090 1lOli 111; 1120 113; 114; 1150 1160 
280 300 
EPVWFGDSDR'ASLGVDKDVYLTI PRGRMKD 
GMCCGGTTTGGTTTGGTGATTCTGATCGCGCGCTTAGT 
1170 11s; 119a 120; 121; 1220 1230 124; 1250 
Fig. 3. The sequence of the BstEII-BgfiI fragment of the mutant and wild-type duck gene. The sequence shown is 
that of the wild-type gene. The alteration caused by the duck 11191 mutation is shown in brackets at nucleotide 643 
and at amino acid 105. The single-letter notation for amino acids is used. 
bacteriophage and were sequenced. All of the se- 
quence of the 683-bp BstEII-BglII fragment of 
pJBS608 was determined and the sequence was 
found to be identical to the wild-type sequence x- 
cept at position 643 (fig. 1) where a G-A transition 
had occurred resulting in a change of glycine-105 
to aspartate-105 in PBP 5. The sequence of this 
region in the wild-type and mutant is shown in fig. 
3. 
4. DISCUSSION 
The block in the deacylation step of the enzyme In [21] it was reported that pCMB has the same 
mechanism of PBP 5 in the dacAlll91 mutant is effect on the activity of D-alanine carboxypep- 
caused by a single nucleotide substitution that tidase 1A as that produced by the dacA11191 
results in the change of glycine-105 to mutation and it was suggested that a cysteine 
aspartate-105. The rate of release of the bound residue is involved in the deacylation step of the 
benzylpenicilloyl moiety in the mutant was about enzyme mechanism but not in the acylation event 
6% of that from wild-type PBP 5. The affinity of [3] We have reinvestigated the effect of pCMB on 
the mutant PBP 5 for benzylpenicillin was also PBP 5 (in preparation) and have shown that both 
altered, being about 2 times lower than that of the the binding and release of penicillin are prevented 
normal enzyme. This may be an underestimate of by this reagent at relatively low concentrations 
the real difference in the affinity between the mu- (< 0.2 mM) and the effect of pCMB on PBP 5 is 
tant and wild-type enzymes ince the concentration 
of benzylpenicillin required to obtain 50% satura- 
tion is likely to be influenced by the differences in 
the rates of deacylation. The dacA11191 mutation 
therefore results in a PBP 5 that is altered in both 
the acylation and deacylation steps of the enzyme 
mechanism. The effect of the deacylation step ap- 
pears, however, to be substantially greater than 
that on the acylation step. This is supported by the 
accumulation of acyl-enzyme when the mutant 
PBP 5 (but not the wild-type PBP 5) is incubated 
with peptide substrates [3]. 
188 
Volume 165, number 2 FEBS LETTERS January 1984 
therefore different from the effect of the 
dacA 11191 mutation which preferentially affects 
the deacylation step of the enzyme mechanism. 
PBP 5 contains only a single cysteine residue 
(cysteine-115) [ 141 and the inhibition of the bin- 
ding and release of penicillin by pCMB can be at- 
tributed to the modification of this residue. It is in- 
teresting that modification of two closely position- 
ed residues (glycine-105 and cysteine-115) 
drastically affects the enzyme mechanism. This 
region may in the three-dimensional structure be a 
part of, or close to, the active site of PBP 5. The 
active site residue that is acylated by penicillin (and 
by substrate) has been assigned as serine-44 on the 
basis of homologies with those D-alanine carboxy- 
peptidases where the acive site serine has been 
determined by chemical methods [2,14]. 
Cysteine-115 could have a catalytic role in the 
mechanism of PBP 5 although modification of this 
residue by pCMB may inactivate the enzyme in- 
directly. Glycine-105 is unlikely to have a catalytic 
role and the effect of the change from glycine-105 
to aspartate-105 caused by the dacA11191 muta- 
tion may result from an alteration of the secondary 
structure of this region. An understanding of the 
importance of these residues for the activity of 
PBP 5 must await the solution of the three- 
dimensional structure of PBPs. 
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